Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVB003
- Development stage
- Unknown
- Lead developer
- VGI Health Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**IVB003** is an investigational small molecule drug candidate developed using a proprietary transmucosal delivery platform, designed for oral administration in capsule form at 120 mg three times daily (360 mg total daily dose). It targets pancreatic adenocarcinoma and is based on tocotrienols, vitamin E isomers known for potential anti-cancer properties through antioxidant and pro-apoptotic mechanisms, though specific mechanism of action details remain undisclosed. Developed by Invictus BioPharma (acquired by Azure Health Technology, previously VGI Health Technology), it has received HREC approval for a Phase II clinical study in pancreatic cancer with progression-free survival as the primary endpoint.
Beyond the preview
Go deeper on IVB003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IVB003.